BERYL DRUGS | ERIS LIFESCIENCES | BERYL DRUGS/ ERIS LIFESCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 51.6 | 50.9 | 101.4% | View Chart |
P/BV | x | 1.9 | 7.2 | 26.9% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BERYL DRUGS ERIS LIFESCIENCES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BERYL DRUGS Mar-24 |
ERIS LIFESCIENCES Mar-24 |
BERYL DRUGS/ ERIS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 45 | 971 | 4.6% | |
Low | Rs | 12 | 565 | 2.1% | |
Sales per share (Unadj.) | Rs | 52.7 | 147.7 | 35.7% | |
Earnings per share (Unadj.) | Rs | 1.5 | 29.2 | 5.2% | |
Cash flow per share (Unadj.) | Rs | 3.9 | 42.6 | 9.1% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 17.6 | 189.7 | 9.3% | |
Shares outstanding (eoy) | m | 5.07 | 136.03 | 3.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.5 | 5.2 | 10.3% | |
Avg P/E ratio | x | 18.7 | 26.3 | 71.0% | |
P/CF ratio (eoy) | x | 7.3 | 18.0 | 40.5% | |
Price / Book Value ratio | x | 1.6 | 4.0 | 39.8% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 144 | 104,470 | 0.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 17 | 4,038 | 0.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 267 | 20,091 | 1.3% | |
Other income | Rs m | 5 | 238 | 2.0% | |
Total revenues | Rs m | 272 | 20,330 | 1.3% | |
Gross profit | Rs m | 22 | 6,748 | 0.3% | |
Depreciation | Rs m | 12 | 1,826 | 0.7% | |
Interest | Rs m | 5 | 848 | 0.6% | |
Profit before tax | Rs m | 10 | 4,312 | 0.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2 | 342 | 0.7% | |
Profit after tax | Rs m | 8 | 3,971 | 0.2% | |
Gross profit margin | % | 8.2 | 33.6 | 24.5% | |
Effective tax rate | % | 23.9 | 7.9 | 301.1% | |
Net profit margin | % | 2.9 | 19.8 | 14.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 105 | 23,790 | 0.4% | |
Current liabilities | Rs m | 61 | 26,090 | 0.2% | |
Net working cap to sales | % | 16.7 | -11.4 | -146.0% | |
Current ratio | x | 1.7 | 0.9 | 190.3% | |
Inventory Days | Days | 14 | 17 | 80.8% | |
Debtors Days | Days | 1,036 | 77 | 1,350.7% | |
Net fixed assets | Rs m | 72 | 44,398 | 0.2% | |
Share capital | Rs m | 51 | 136 | 37.4% | |
"Free" reserves | Rs m | 38 | 25,675 | 0.1% | |
Net worth | Rs m | 89 | 25,811 | 0.3% | |
Long term debt | Rs m | 24 | 6,545 | 0.4% | |
Total assets | Rs m | 177 | 68,188 | 0.3% | |
Interest coverage | x | 3.1 | 6.1 | 51.4% | |
Debt to equity ratio | x | 0.3 | 0.3 | 106.2% | |
Sales to assets ratio | x | 1.5 | 0.3 | 512.4% | |
Return on assets | % | 7.0 | 7.1 | 99.3% | |
Return on equity | % | 8.6 | 15.4 | 56.0% | |
Return on capital | % | 13.1 | 15.9 | 82.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0.1 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 23 | 0.0% | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 23 | 0.0% | |
Net fx | Rs m | 0 | -23 | -0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8 | 4,860 | 0.2% | |
From Investments | Rs m | -11 | -18,545 | 0.1% | |
From Financial Activity | Rs m | 1 | 13,798 | 0.0% | |
Net Cashflow | Rs m | -2 | 382 | -0.4% |
Indian Promoters | % | 26.4 | 54.9 | 48.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 26.6 | - | |
FIIs | % | 0.0 | 8.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 73.6 | 45.1 | 163.1% | |
Shareholders | 7,364 | 46,346 | 15.9% | ||
Pledged promoter(s) holding | % | 0.0 | 18.5 | - |
Compare BERYL DRUGS With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BERYL DRUGS | ERIS LIFESCIENCES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 5.88% | 0.46% | 0.69% |
1-Month | -2.29% | 7.54% | -0.78% |
1-Year | 72.73% | 44.85% | 42.85% |
3-Year CAGR | 48.80% | 22.64% | 20.14% |
5-Year CAGR | 46.14% | 27.07% | 26.11% |
* Compound Annual Growth Rate
Here are more details on the BERYL DRUGS share price and the ERIS LIFESCIENCES share price.
Moving on to shareholding structures...
The promoters of BERYL DRUGS hold a 26.4% stake in the company. In case of ERIS LIFESCIENCES the stake stands at 54.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BERYL DRUGS and the shareholding pattern of ERIS LIFESCIENCES.
Finally, a word on dividends...
In the most recent financial year, BERYL DRUGS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
ERIS LIFESCIENCES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BERYL DRUGS, and the dividend history of ERIS LIFESCIENCES.
For a sector overview, read our pharmaceuticals sector report.
Asian markets traded higher on Friday, following the overnight rally on Wall Street, and the release of economic data in the region.